SynthesisBMC cancer2025

The benefit and risk of addition of PD-1/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis.

Deping Luo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.